CD8A and neoplasm: Treatment with Delta24-RGD creates a pro-inflammatory environment in the tumor by the upregulation of several cytokines, chemokines and the recruitment of F4/80+ macrophages, CD8+ and CD4+ T cells (figure 4, 5).